Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Long-Term Investments (2018 - 2025)

BioNexus Gene Lab's Long-Term Investments history spans 8 years, with the latest figure at $237760.0 for Q3 2025.

  • For Q3 2025, Long-Term Investments fell 2.04% year-over-year to $237760.0; the TTM value through Sep 2025 reached $237760.0, down 2.04%, while the annual FY2024 figure was $1.3 million, N/A changed from the prior year.
  • Long-Term Investments for Q3 2025 was $237760.0 at BioNexus Gene Lab, down from $1.2 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $1.7 million in Q2 2024 and bottomed at $237760.0 in Q3 2025.
  • The 5-year median for Long-Term Investments is $1.0 million (2022), against an average of $997885.4.
  • The largest annual shift saw Long-Term Investments surged 35579.89% in 2021 before it plummeted 84.35% in 2024.
  • A 5-year view of Long-Term Investments shows it stood at $749027.0 in 2021, then surged by 53.65% to $1.2 million in 2022, then surged by 34.78% to $1.6 million in 2023, then decreased by 18.44% to $1.3 million in 2024, then plummeted by 81.21% to $237760.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Long-Term Investments are $237760.0 (Q3 2025), $1.2 million (Q2 2025), and $1.3 million (Q4 2024).